Ataxia-pancytopenia syndrome

Ataxia-pancytopenia syndrome, also known as cerebellar ataxia with progressive bone marrow failure, is an extremely rare inherited disorder characterized by the combination of cerebellar ataxia (impaired coordination and balance due to dysfunction of the cerebellum) and pancytopenia (a reduction in all three major blood cell types: red blood cells, white blood cells, and platelets). The condition primarily affects the nervous system and the hematopoietic (blood-forming) system. It has been linked to pathogenic variants in the SAMD9L gene on chromosome 7q21.2, which plays a role in cell proliferation and innate immune responses. Key clinical features include progressive cerebellar ataxia with gait instability, dysarthria (difficulty with speech), and nystagmus (involuntary eye movements). The hematological manifestations include bone marrow failure leading to pancytopenia, which can result in anemia, increased susceptibility to infections due to low white blood cell counts, and bleeding tendencies from low platelet counts. Some patients may also develop immunodeficiency and have an increased risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) due to the underlying bone marrow dysfunction. Monosomy 7 or deletion of chromosome 7q may be observed in bone marrow cells. There is no specific cure for ataxia-pancytopenia syndrome. Treatment is primarily supportive and symptom-directed. Hematological complications may require blood transfusions, growth factor support, or in severe cases, hematopoietic stem cell transplantation (bone marrow transplant). Neurological symptoms are managed with physical therapy, occupational therapy, and speech therapy. Regular monitoring by both hematology and neurology specialists is essential for early detection of complications, particularly the development of myelodysplastic syndrome or leukemia.

Common questions about Ataxia-pancytopenia syndrome